Starting PEP within 2 hours of HIV exposure can provide protection, but each subsequent hour reduces effectiveness incrementally. Post-exposure prophylaxis (PEP) works by flooding your system with antiretroviral medications before HIV can establish permanent infection in your body.
After exposure, HIV takes time to integrate into your DNA. PEP intercepts this process by blocking viral replication at multiple stages. The treatment uses the same antiretroviral drugs given to people living with HIV, but as a 28-day course designed to prevent initial infection rather than manage ongoing disease.
PEP effectiveness relies on three interconnected factors: how quickly you start treatment, how consistently you take the medications, and whether the prescribed regimen matches your specific exposure type.
The 72-Hour Window
HIV doesn’t cause immediate infection upon exposure. The virus must first attach to CD4 cells (a type of immune cell), enter them, convert its RNA to DNA using reverse transcriptase (an enzyme the virus uses to copy its genetic material), and integrate that DNA into your cellular genome.
Starting PEP within 2 hours of exposure can provide protection. Each subsequent hour reduces effectiveness incrementally. By 24 hours post-exposure, protection remains substantial but diminished. At 48 hours, effectiveness drops further. Beyond 72 hours, viral integration has likely occurred, making PEP ineffective.
This timeline applies from the moment of exposure, not from when you notice or confirm it. If uncertainty exists about exact timing, healthcare providers typically calculate from the earliest possible exposure point.
How Antiretroviral Medications Prevent Infection
Modern PEP regimens combine three antiretroviral drugs attacking HIV at different stages:
Tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) blocks reverse transcriptase (the enzyme HIV uses to convert its genetic material). This prevents HIV from converting its genetic material into a form compatible with human cells. Without this conversion, the virus cannot proceed to integration.
Emtricitabine (FTC) works similarly to tenofovir but targets a different site on reverse transcriptase. Using both creates redundancy. If HIV develops partial resistance to one, the other maintains suppression.
Dolutegravir or raltegravir inhibits integrase (the enzyme HIV uses to insert its DNA into your chromosomes). This prevents the virus from inserting its DNA into your chromosomes. Even if reverse transcription partially succeeds, integration inhibitors provide a second barrier.
This triple-drug approach ensures that HIV faces obstacles at multiple replication stages simultaneously.
Factors That Influence Treatment Success
Exposure Type and Viral Load
Different exposure routes carry different transmission risks. Receptive anal intercourse presents a higher transmission probability than insertive intercourse. Needle-sharing injuries involve direct blood contact. The source’s viral load (the amount of HIV in their blood) significantly affects transmission likelihood. Undetectable viral loads in people on established HIV treatment dramatically reduce transmission risk.
Your healthcare provider assesses these factors when prescribing PEP. High-risk exposures warrant immediate treatment. Lower-risk situations may involve risk-benefit discussions about whether PEP provides meaningful protection.
Adherence Throughout 28 Days
PEP requires taking medications every day for four weeks without missing doses. Antiretroviral drugs maintain protective blood levels only with consistent dosing. Missing even a few doses creates gaps in protection during which HIV can replicate.
Common adherence challenges include:
- Gastrointestinal side effects (such as nausea or diarrhoea) peaking in the first week
- Fatigue that can affect daily routines
- The psychological burden of maintaining a strict medication schedule
- Social situations where taking medications feels awkward
Discussing these challenges with your healthcare provider before they derail treatment improves outcomes.
Drug Interactions and Absorption
Certain medications, supplements, and substances interact with PEP drugs. Antacids containing aluminium or magnesium reduce tenofovir absorption if taken simultaneously. Some herbal supplements affect drug metabolism. Recreational substances may impact both medication effectiveness and your ability to maintain adherence.
Disclose all medications and substances to your prescribing doctor. Timing adjustments or alternative formulations can often resolve interaction concerns.
Managing Side Effects Without Compromising Treatment
Side effects are common during the first several days as your body adjusts to the medications:
Nausea is common among people starting PEP. Taking medications with food reduces stomach upset. If nausea persists, anti-nausea medications can help without affecting PEP effectiveness.
Diarrhoea typically resolves within the first week. Staying hydrated and eating bland foods helps manage symptoms. Severe diarrhoea affecting medication absorption requires medical evaluation.
Fatigue and headaches commonly accompany the first week of treatment. These generally improve without intervention as your body adapts.
Insomnia occurs with some regimens. Taking medications in the morning rather than the evening may help if sleep disturbances develop.
Stopping PEP due to side effects eliminates protection entirely. Working with your healthcare provider to manage symptoms while continuing treatment maintains effectiveness.
Testing Schedule During and After PEP
PEP requires baseline and follow-up testing:
At PEP initiation: HIV testing confirms you’re not already infected (PEP treats exposure, not established infection). Kidney function testing ensures your body can process tenofovir safely. Hepatitis B screening (a blood test checking for hepatitis B infection) guides treatment decisions since some PEP drugs also treat hepatitis B.
During treatment: Your provider may schedule a check-in appointment to assess adherence, manage side effects, and address concerns.
At several weeks post-PEP: HIV testing determines whether PEP successfully prevented infection.
At 3 months post-exposure: Final HIV testing provides definitive confirmation. The 3-month window accounts for the rare possibility of delayed antibody development.
Complete the entire testing schedule even if you have finished all 28 days of medication. Testing confirms treatment success and provides peace of mind.
What Our Men’s Health Specialist Says
PEP can work when started promptly and taken consistently. Focusing on the concrete steps, starting treatment quickly, taking each dose, and managing side effects proactively can produce outcomes. People who complete PEP as prescribed generally do not acquire HIV from the exposure that prompted treatment.
Putting This Into Practice
- Seek medical attention immediately after potential exposure. Don’t wait to see if symptoms develop or attempt to assess risk yourself. Medical evaluation within hours provides protection.
- Set medication reminders on your phone. Consistent daily dosing maintains protective drug levels. Choose a time that fits your routine and stick to it throughout the 28 days.
- Prepare for common side effects. Stock anti-nausea medication, stay hydrated, and plan for lower energy during the first week. Anticipating challenges makes them easier to manage.
- Communicate openly with your healthcare provider. Report side effects, adherence struggles, or concerns promptly. Adjustments are possible without compromising protection.
- Complete all follow-up testing. Testing at prescribed intervals confirms treatment success and identifies any issues requiring attention.
When to Seek Professional Help
- Potential HIV exposure occurred within the past 72 hours
- You’re currently on PEP and experiencing severe side effects affecting your ability to take medications
- You’ve missed multiple PEP doses and need guidance on continuing treatment
- Your PEP course ended, and you need follow-up testing
- You’re uncertain whether an exposure warrants PEP treatment
- You experience symptoms suggesting acute HIV infection during or after PEP
Commonly Asked Questions
Can PEP fail even with complete adherence?
PEP failure with complete adherence is rare. Documented failures typically involve delayed initiation beyond 72 hours, inconsistent dosing, drug-resistant HIV strains (uncommon), or exposures larger than initially assessed.
Does the type of PEP regimen affect effectiveness?
Currently recommended PEP regimens can provide comparable protection when taken as prescribed. Regimen selection considers factors like potential drug interactions, kidney function, and side effect profiles rather than effectiveness differences.
Should I use condoms during the 28-day PEP course?
Yes. PEP protects against the specific exposure that prompted treatment, not new exposures during the treatment period. Using barrier protection prevents additional potential transmissions and reduces the risk of other sexually transmitted infections.
How soon after completing PEP can I know if it worked?
Initial testing at several weeks post-PEP provides preliminary results. Definitive confirmation comes from testing at 3 months post-exposure. This timeline accounts for the window period during which HIV antibodies develop to detectable levels.
Will taking PEP affect my health long-term?
A 28-day PEP course causes no lasting health effects in people with normal kidney function. The medications clear from your system within days of completing treatment. Any side effects resolve once you stop taking the drugs.
Next Steps
Start PEP within 72 hours of exposure—ideally within hours—to maximise protection. Complete all 28 days of medication without missing doses. Attend all follow-up testing appointments at several weeks and 3 months post-exposure.
If you’ve experienced potential HIV exposure within the past 72 hours, consult a men’s health physician immediately for PEP evaluation and treatment.
